Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatitis B Vaccination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    290 result(s) found for: Hepatitis B Vaccination. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-002589-38 Sponsor Protocol Number: HBV-2013 Start Date*: 2013-07-11
    Sponsor Name:Universität Innsbruck, Institut für Biomedizinische Alternsforschung
    Full Title: Primary and booster vaccination in old age: Hepatitis A and Hepatitis B
    Medical condition: This study will analyze cellular and humoral immune reponses after primary or booster vaccination against HAV and HBV. Healthy adults will be vaccinated with a combination vaccine, which is license...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10054181 Hepatitis B immunization LLT
    16.1 100000004865 10063436 Hepatitis A immunization LLT
    16.1 100000004865 10068384 Hepatitis immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001744-53 Sponsor Protocol Number: PAI study Start Date*: 2008-04-02
    Sponsor Name:University of Leipzig
    Full Title: Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not...
    Medical condition: Hepatitis B immunization
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054130 Hepatitis B immunisation LLT
    9.1 10054130 Hepatitis B immunisation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003649-18 Sponsor Protocol Number: V232-059-00 Start Date*: 2007-01-12
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process
    Medical condition: Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019731 Hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000923-33 Sponsor Protocol Number: HepB/APAP/2011 Start Date*: 2011-07-14
    Sponsor Name:Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
    Full Title: Effects of paracetamol use on the immune response after hepatitis B vaccination
    Medical condition: No medical conditions will be studied. The association between timing of the use of paracetamol during hepatitis B vaccination and the development of an antibody response will be studied in student...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    13.1 10022891 - Investigations 10033765 Paracetamol normal LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021473-36 Sponsor Protocol Number: KB050 Start Date*: 2011-11-22
    Sponsor Name:KEDRION
    Full Title: Efficacy and Safety evaluation of Kedrion Human Hepatitis B Immunoglobulin for intramuscular use in the prevention of hepatitis B in the newborns of Hepatitis B Virus carrier-mothers: multi-centr...
    Medical condition: Newborns of hepatitis B virus carrier mothers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019619 Hep B LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001639-23 Sponsor Protocol Number: V232-058 Start Date*: 2006-09-05
    Sponsor Name:Merck SHARP & DOHME DE ESPAÑA
    Full Title: A Study to Assess the Anamnestic Immune Response 4 to 6 Years After a Primary Vaccination Series With HBVAXPRO™ Estudio para evaluar la respuesta inmune anamnésica 4 a 6 años después de una pauta d...
    Medical condition: Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    7.1 10019731 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004099-31 Sponsor Protocol Number: 116811 Start Date*: 2016-07-26
    Sponsor Name:Glaxosmithkline Biologicals
    Full Title: Long-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix™-B.
    Medical condition: Healthy volunteers (immunisation against infection caused by all known subtypes of hepatitis B virus).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003756-32 Sponsor Protocol Number: HEP/UNI-001 Start Date*: 2016-06-10
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: A pilot study evaluating the influence of chronobiology on Hepatitis B responses in health-care students attending the University of Salford
    Medical condition: The immune response to Hepatitis B vaccine is being investigated.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10019732 Hepatitis B antibody PT
    20.0 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    Population Age: Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005023-18 Sponsor Protocol Number: V232-054-00 Start Date*: 2005-06-09
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: Study in Healthy Young Adults to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade
    Medical condition: Acute hepatitis B without delta-agent and without hepatic coma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10019731 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-006743-31 Sponsor Protocol Number: DV2-HBV-10 Start Date*: 2007-06-12
    Sponsor Name:Dynavax Technologies Corporation
    Full Title: A Phase III Safety and Efficacy Study to Compare Immune Responses following Injection with Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®
    Medical condition: Prevention of Hepatitis B Virus (HBV) infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054181 Hepatitis B immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016721-33 Sponsor Protocol Number: rHB01C Start Date*: 2010-09-09
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥ 50 years old) Vaccinated With a Primary Series of an Hepatitis B Vaccine
    Medical condition: Healthy subjects, active immunisation against Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019731 Hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022538-10 Sponsor Protocol Number: 112688 Start Date*: 2011-04-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (Engerix-B™ Kinder) vaccine challenge in children...
    Medical condition: Antibody persistence and hepatitis B vaccine challenge in children aged 7–8 years, previously primed and boosted with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) as part of...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019731 Hepatitis B LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000110-21 Sponsor Protocol Number: BT959 Start Date*: 2006-11-21
    Sponsor Name:Biotest AG
    Full Title: An open, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application for perinatal prophylaxis in infan...
    Medical condition: Healthy mature male and female neonates of gestational week ≥ 37+0 with indication for hepatitis B prophylaxis due to a HBsAg positive mother.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054130 Hepatitis B immunisation LLT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005629-25 Sponsor Protocol Number: 215301 Start Date*: 2022-08-25
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 1/2a, open-label, randomised, controlled, multi-country, dose-escalation study to assess the safety and immunogenicity of AS37 in combination with the Hepatitis B surface antigen (HBsAg), a...
    Medical condition: Healthy volunteers (Hepatitis B Virus infection)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003981-15 Sponsor Protocol Number: V232-056 Start Date*: 2016-09-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process
    Medical condition: Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001820-22 Sponsor Protocol Number: Sci-B-Vac–002 Start Date*: 2018-02-20
    Sponsor Name:VBI Vaccines INC.
    Full Title: A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
    Medical condition: Hepatitis B Vaccination
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10054181 Hepatitis B immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005939-10 Sponsor Protocol Number: V232-055 Start Date*: 2006-05-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A study in healthy, young adults and healthy infants of the safety, tolerability, and immunogenicity of an investigational manufacturing process for the recombinant hepatitis B vaccine
    Medical condition: Hepatitis B ICD10 classification code : Hepatitis Viral- Type B (ICD10- B16) MedDRA classification code : Infections and Infestations – Viral Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    7.1 10019731 LLT
    Population Age: Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000557-21 Sponsor Protocol Number: HEPBARE-2015-01 Start Date*: 2015-06-12
    Sponsor Name:Vall de Hebron Hospital
    Full Title: Immunogenicity and efficacy of the vaccine against Hepatitis B virus in immunosuppressed patients antiHBc positive with low titers of anti-HBs. Assessment of clinical usefulness in preventing react...
    Medical condition: Patients under immunosuppressant therapy with past hepatitis B infection (HBsAg -/antiHBc +) but low antiHBs titers.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10058827 Hepatitis B reactivation LLT
    18.0 10022891 - Investigations 10050542 Hepatitis B surface antigen negative PT
    18.0 10022891 - Investigations 10052328 Hepatitis B core antigen positive PT
    18.0 100000004865 10068384 Hepatitis immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000261-38 Sponsor Protocol Number: 108988 Start Date*: 2008-01-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Bio...
    Medical condition: Hepatitis B vaccine challenge dose given to subjects, 17 to 21 years of age, to evaluate immune memory to Hepatitis B antigen, approximately 6 years after priming with Hepatitis B vaccine.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003950-10 Sponsor Protocol Number: 116722 Start Date*: 2013-04-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a challenge dose of Engerix™-B Kinder in adolesce...
    Medical condition: Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:06:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA